[10] In 1997, Quackenbush joined the faculty of The Institute for Genomic Research (TIGR) in Rockville, Maryland,[10] where his focus began to shift to post-genomic applications, with an emphasis on microarray analysis.
The consortium aims to use genomic technologies and advanced data-analysis tools on available patient lung-tissue samples to gain new insights into pulmonary disease and thus develop more effective, personalized treatments.
He was also awarded a four-million-dollar fellowship bestowed by Australia's National Health and Medical Research Council to study chemotherapy resistant ovarian cancers in collaboration with colleagues at the University of Queensland's Institute for Molecular Bioscience.
Quackenbush is also a member of the scientific advisory boards of a number of biotech and precision medicine companies, including Caris Life Sciences, SynapDx, Perthera, and NABsys.
[citation needed] In 2011, Quackenbush, along with partner Mick Correll, founded Genospace, a software company focused on developing tools to enable precision genomic medicine.